ACADIA Pharma (NASDAQ:ACAD): Q2 GAAP EPS of -$0.38 beats by $0.08.
Revenue of $83.21M (+45.8% Y/Y) beats by $10.71M.
Shares +1.7%.
Wednesday, July 31, 2019
Teladoc Q2 top line up 38%, shares down 3% after hours as losses continue
Teladoc (NYSE:TDOC) Q2 results ($M): Revenues: 130.3 (+37.7%); Subscription Access Fees: 111.2 (+39.3%).
Net loss: (29.3) (-16.7%); loss/share: (0.41) (-2.5%).
Cash flow ops (6 mo.): (1.7) (+90.3%).
Total visits: 908K (+70.4%).
Q3 guidance: Revenue: $135M – 138M; non-GAAP EBITDA: $7M – 9M; loss/share: ($0.42 – 0.40).
2019 guidance: Revenue: $538M – 545M from $535M – 545M; non-GAAP EBITDA: $27M – 33M from $25M – 35M; loss/share: ($1.60 – 1.52) from ($1.66 – 1.52).
Shares down 3% after hours.
Previously: Teladoc Health EPS in-line, beats on revenue (July 31)
DexCom Q2 top line up 39%, guidance raised
Net income: (10.5) (-134.8%); non-GAAP net income: 7.8 (+220.0%); EPS: (0.12) (-135.3%); non-GAAP EPS: 0.08 (+214.3%).
2019 guidance: Revenues: $1.325B – 1.375B from $1.250B – 1.300B.
Shares are down 3% after hours.
Previously: DexCom EPS beats by $0.08, beats on revenue (July 31)
Hologic FQ3 revenues up 3%; ytd cash flow down 20%
Hologic (NASDAQ:HOLX) fiscal Q3 results ($M): Revenues: 852.4 (+3.4%); Diagnostics: 305.4 (+3.8%); Breast Health: 325.4 (+5.7%).
Net income: 93.9 (-16.8%); non-GAAP net income: 171.6 (+7.9%); EPS: 0.35 (-14.6%); non-GAAP EPS: 0.63 (+8.6%).
Cash flow ops (9 mo.): 401.8 (-19.7%).
Fiscal Q4 guidance: Revenues: $834M – 849M; EPS: $0.39 – 0.41; non-GAAP EPS: $0.64 – 0.66.
Fiscal 2019 guidance: Revenues: $3.335B – 3.350B from $3.325B – 3.345B; EPS: $0.09 – 0.11 from $0.06 – 0.09; non-GAAP EPS: $2.42 – 2.44 from $2.41 – 2.44.
Shares down 1% after hours.
Previously: Hologic EPS beats by $0.02, beats on revenue (July 31)
https://seekingalpha.com/news/3484797-hologic-fq3-revenues-3-percent-ytd-cash-flow-20-percent
Apellis Pharmaceuticals EPS beats by $0.17
Apellis Pharmaceuticals (NASDAQ:APLS): Q2 GAAP EPS of -$0.61 beats by $0.17.
Cash and cash equivalents of $289.13M
Welltower adjusts 2019 FFO guidance, sells Benchmark portfolio
Welltower (NYSE:WELL) revises its 2019 guidance for normalized FFO per share to $4.10-$4.20 from its previous range of $4.10-$4.25.
Compares with consensus of $4.19.
Boosts 2019 average blended same-store net operating income growth guidance to 2.0%-2.5% vs. prior range of 1.25%-2.25%.
Boosts 2019 expected disposition proceeds to $3.1B at blended yield of 6.3% vs. prior view of $1.4B at blended yield of 6.2%.
Q2 normalized FFO per share of $1.05, beating the consensus of $1.04, increased from $1.00 in the year-ago quarter.
Q2 total portfolio same-store NOI increased by 3.1%, driven by performance across all property types.
Other announcements:
In July, Welltower sold its the Benchmark Senior Living portfolio for $1.8B with the potential to receive an additional $50M in earnout proceeds.
Expands relationship with Summit Medical Group by agreeing to acquire a 43-acre medical campus encompassing 270,000 square feet across 6 buildings in Berkeley Heights, New Jersey for $140M; medical campus will be master leased by Summit under a new 20-year, absolute net lease.
Acquires a six-community portfolio in Denver and Boulder regions for $308M in partnership with Balfour Senior Living.
Conference call on Aug. 1 at 9:00 AM ET.
Previously: Welltower FFO beats by $0.01, beats on revenue (July 31)
Subscribe to:
Posts (Atom)